Protocol Number: 97-H-0202

Title:

Low Intensity Preparative Regimen Followed by HLA-Matched, Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematologic Malignancies in Older Adults

Number:

97-H-0202

Summary:

Diseases such as leukemia, lymphoma, and multiple myeloma fall into the category of blood cancers. Some of these conditions can now be cured by bone marrow transplantation (BMT). The ability of BMT to cure these conditions has been credited to the use of high doses of chemotherapy, radiation therapy, and the antileukemia effect of the transplant.

Because the effectiveness of BMT relies on the use of high doses of chemotherapy and total body irradiation (TBI), it is a therapy associated with toxic side effects. These side effects are often deadly and have limited BMT for use in patients under the age of 55.

In this study researchers plan to treat older patients between the ages of 55 to 75 years with blood cell transplants taken from donors who are genetically matched relatives of the patient. In order to decrease the toxic side effects associated with the transplant, researchers will not use chemoradiotherapy. Instead they plan to use intensive immunosuppressive therapy and allow the transplanted cells to take effect.

Sponsoring Institute:

National Heart, Lung and Blood Institute (NHLBI)

Recruitment Detail

Type: Completed Study; data analyses ongoing

Gender: Male & Female

Referral Letter Required: No

Population Exclusion(s): Children

Eligibility Criteria: This study is not currently recruiting new subjects. If you have questions about participating in a study, please contact the Patient Recruitment and Public Liaison Office, CC.

Special Instructions:

Currently Not Provided

Keyword(s):

Peripheral Blood Stem Cells

Engraftment

Fludarabine

Nonmyeloablative

Graft-Versus-Leukemia

Graft vs. Host Disease

Cyclophosphamide

Donor Apheresis

Nonmyeloablative Bone Marrow Transplantation

Recruitment Keyword(s):

Chronic Myelogenous Leukemia (CML)

Acute Lymphoblastic Leukemia (ALL)

Acute Myelogenous Leukemia (AML)

Myelodysplastic Syndromes

Chronic Lymphocytic Leukemia (CLL)

Prolymphocytic Leukemia

Condition(s):

Chronic Lymphocytic Leukemia

Graft vs Host Disease

Leukemia

Myelodysplastic Syndrome

Myeloid Leukemia

Investigational Drug(s):

None

Investigational Device(s):

None

Interventions:

Procedure/Surgery: Blood cell transplantation

Supporting Site:

National Heart, Lung and Blood Institute

Contact(s):

This study is not currently recruiting new subjects. If you have questions about participating in a study, please contact the Patient Recruitment and Public Liaison Office, CC.

Citation(s):

Stem cell transplantation (SCT) for chronic lymphocytic leukemia (CLL): graft-versus-leukemia (GVL) without acute graft-versus-host disease (GVHD)

Engraftment of allogeneic hematopoietic progenitor cells with purine analog containing chemotherapy

Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by Filgastrim (G-CSF)

• Questions about participating in a study, please contact the Patient Recruitment and Public Liaison Office, CC.
• Technical questions regarding the Clinical Center web site, please contact the Department of Networks and Applications, CC.

Search The Studies | Help | Questions |
Clinical Center Home | NIH Home

National Institutes of Health Clinical Center
Bethesda, Maryland 20892. Last update: 09/16/2008